Acelyrin is a late-stage clinical biopharma company led by co-founder and CEO Shao-Lee Lin, MD, PhD, focused on identifying, acquiring, accelerating development, and commercializing promising drug candidates. The company holds global development and commercialization rights to izokibep under an exclusive licensing arrangement with Affibody AB, including rights in the United States, European Union, and Japan (excluding select Asian countries). Acelyrin is advancing izokibep in hidradenitis suppurativa (HS) and uveitis and plans to explore several potential new indications. The company also intends to pursue portfolio expansion through high-value business development opportunities. Financially, Acelyrin completed a $300M Series C financing to fund these development and expansion plans.

Total raised

$300M

Funding rounds

1

Latest round

Series C

Latest activity

Sep 2022